Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22584709 | 0.81 | CYP3A4 (0.46) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL28709541 | 0.81 | CYP3A4 (0.46) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL28705734 | 0.81 | GPR119 (0.43) | CYP3A4TSHRCYP2D6CYP2C19MAPK1 | |
| SCHEMBL4840835 | 0.81 | CHRM2 (0.48) | CYP3A4DTYMKGPR119POLB | |
| SCHEMBL4773996 | 0.80 | GPR119 (0.51) | CYP3A4GPR119 | |
| SCHEMBL28872036 | 0.80 | TSHR (0.51) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL209379 | 0.79 | TSHR (0.59) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL1087873 | 0.79 | CYP3A4 (0.43) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL1087874 | 0.79 | CYP3A4 (0.43) | CYP3A4TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL209862 | 0.79 | CHRM2 (0.44) | CYP3A4SMN1; SMN2DTYMKGPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2023-05-30 | — | — | US | disclosed |
| CN-109563092-B | 2-phenylimidazo [4,5-B ] pyridin-7-amine derivatives useful as inhibitors of the activity of the mammalian tyrosine kinase ROR1 | 坎塞拉有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | CYP3A4 439/4885TSHR 2859/4885CYP2D6 1028/4885 |
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | CYP3A4 1966/4885TSHR 1024/4885CYP2D6 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.